Concord Drugs Ltd. benchmarking: Perfomance to industry peers

Financial

	Concord Drugs	Mercury Laboratories	Curis Lifesciences
Operational Metrics
Financials
5 yr Average ROE	2.78 %	10.51 %	63.11 %
5yr average Equity Multiplier	1.87	1.49	1.91
5yr Average Asset Turnover Ratio	0.84	1.05	1.07
5yr Avg Net Profit Margin	1.59 %	6.6 %	8.37 %
Price to Book	2.88	1.88	6.22
P/E	172.69	21.46	16.52
5yr Avg Cash Conversion Cycle	233.27 Days	-4.69 Days	45.79 Days
Inventory Days	152.22 Days	32.68 Days	77.61 Days
Days Receivable	106.22 Days	115.65 Days	65.45 Days
Days Payable	74.71 Days	157.73 Days	245.93 Days
5yr Average Interest Coverage Ratio	1.69	15.15	5.43
5yr Avg ROCE	8.41 %	13.49 %	36.41 %
5yr Avg Operating Profit Margin	9.1 %	11.74 %	16.92 %
5 yr average Debt to Equity	0.55	0.13	0.12
5yr CAGR Net Profit	-26.55 %	-10.08 %	65.64 %
5yr Average Return on Assets	1.46 %	7.02 %	9.21 %
Shareholdings
Promoter Holding	54.39 %	73.66 %	n/a
Share Pledged by Promoters	0.0	0.0	n/a
Change in Promoter Holding (3 Yrs)	5.39 %	0.0	n/a
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	n/a

	Concord Drugs	Mercury Laboratories	Curis Lifesciences
Product Wise Break-Up	Product Wise Break-Up Sterile Ophthalmic Ointment 0 Oral Liquid 0 0 Capsules 0 Tablet 0 Others 100	Product Wise Break-Up Tablet 0 Sterile Ophthalmic Ointment 0 Capsules 0 0 Oral Liquid 0 Others 100	Product Wise Break-Up Tablet 87.9 Sterile Ophthalmic Ointment 0.12 Capsules 2.23 External Preparation (Cream/Gel/Ointment) 4.18 Oral Liquid 4.59 Others 0.98